

Hadasit
Bio-Holdings Ltd.



HBL

Legal Clarification

This presentation does not constitute an offer to purchase Company's securities or an invitation to receive offers, and is intended to provide only general information, partial in nature, with the aim of providing explanations about the Company to investors and analysts.

This presentation is intended solely as a summary and for the sake of convenience only and cannot replace reviewing Company reports issued to the public, including full information about the Company, before taking a decision regarding investment in Company securities.

This presentation contains forward-looking information, as defined in the Securities Law, 5728-1968. This information includes, among others, projections, objectives, estimates and assumptions, including data presented by way of illustrations and/or graphs and/or tables, relating to events and/or future matters whose realization is uncertain, and is not under Company's control. Forward-looking statement is not a proven fact and by nature is governed by significant non-realization risks. Such data is uncertain, cannot be accurately assessed in advance, and its realization or non-realization will be affected by risk factors, among others, that characterize the Company's activities, as well as general environment developments and external factors affecting Company's activity, which cannot be estimated in advance and are not under Company's control. Accordingly, the readers of this presentation are cautioned that actual results and achievements of the Company in the future may differ materially from those presented in the forward-looking statements contained in this presentation. Also, forward-looking projections and estimates are based on data and information held by the Company at the time of the presentation's preparation, and the Company does not undertake to update and/or change the forecast and/or the estimate as previously mentioned, in order to reflect events and/or circumstances that occurred after the date of preparation of this presentation.

HBL

Founded in 2005, Hadasit Bio-Holdings Ltd. ("HBL") is a publicly-traded holding company (TASE: HDST / OTCQB: HDASY 1:20)

We function as a public gateway to the emerging Israeli biotech market, through our longstanding partnership with Hadassah University Medical Center in Jerusalem and by identifying investments in promising, early-stage life science companies.

We advance our portfolio companies with high potential to become a leading biotech companies by accompany them to the inflection point in which we aim for commercialization in order to enhance value for our investors.

The potential of our portfolio companies is underscored by the quality of our co-investors, which include Sanofi, CLAL Biotechnology Industries, Pontifax, TEVA and BioTime.






STRUCTURE

HBL

36% Hadasit (100% Hadassah)




55% Public

9% Ciano Investments Ltd. UK Private Equity



PORTFOLIO PARTNERS

HBL



TEVA

BIOTIME

Private
Group

CBI CLAL
BIOTECHNOLOGY
INDUSTRIES



SANOFI

Recipharma
good for business

Pontifax

CBI CLAL
BIOTECHNOLOGY
INDUSTRIES

Micromedic
Life Saving Cancer Diagnostics


PORTFOLIO SEGMENTS




Cell Therapy
Dry AMD
and CNS




**Cell Therapy &
Immune Therapy** for
Autoimmunity and
Inflammatory




**Innovative
Drugs**
For CNS



**Dual Signaling
Proteins For**
Cancer and
Autoimmunity



Antibodies for
Autoimmunity
and
Inflammatory



**Multi
Biomarker**
Diagnostics For
Colorectal
Cancer

HBL

A gateway to Israeli Biotech

Experienced, well-respected team affords access to broad network and pipeline of investment and collaboration candidates

- Government
- Private investors
- Established companies
- Start-ups

THE TEAM



TAMI KFIR
CEO

Vast experience in investments management, commercialization and cross-boarder deals. Over 20 years in the biotech industry in various executive positions including Venture Partner at Infinity IP Bank and VP Licensing Healthcare at Yissum.



LIAT HADAD SIMHAYOFF
CFO

CFO Since June 2012. Prior to joining HBL Mrs. Hadad Simhayoff worked in Deloitte Israel, handling a variety of cases including start-ups, public and private companies and non-profit institutions.



YIGAL ERLICH
CHAIRMAN

Founder and Managing Partner at the Yozma Group, Israel's first VC fund. Considered a pioneer in Israeli venture capital. Former Chief Scientist of Israel's Ministry of Economy.



YORAM AZULAI
INVESTMENT MANAGER

Over 20 year of financial experience in biotechnology and medical device private and public companies as well as holdings companies.

HBL - FACTS & FIGURES

\$32M – Raised to date

\$23M – Invested in portfolio companies

- \$15M Received in grants from OCS
- \$31M Additional investments from strategic partners and investors in portfolio companies


HADASSAH UNIVERSITY HOSPITAL

Value Creation through Close Collaboration

- Leading research hospital in Israel
- Renowned clinicians & clinical trial facilities
- #1 in clinical performance in Israel
- Proven experience in identifying unmet medical needs



THE HBL MODEL



PORTFOLIO





Chief Executive Officer
Alon Moran, LLB, MBA

Therapeutic focus: Cell therapy solution for immune tolerance induction in autoimmune and inflammatory conditions including graft-versus-host disease (GvHD) in bone marrow transplants, solid organ transplant rejection and Crohn's disease

Lead product candidate: ApoCell, granted orphan drug designation for GvHD from U.S. FDA in 2013 and from EU. EMA in 2015

Stage: Completed Phase I/II in GvHD; preparing for Phase IIb trial

Pipeline indication: Crohn's, rheumatoid arthritis, gouty arthritis, multiple sclerosis

Competitive Advantage


Autologous therapy derived from patient's own cells enabling patient-specific treatments. Potential replacement for commonly used immune suppression therapies.

Market Opportunity:

- GvHD market to reach ~\$615 million in 2018
- More than 30,000 bone-marrow transplants annually, approx. 30% of patients develop GvHD
- Autoimmune diseases (aggregate) > \$20 billion

Investments: \$15M

- HBL (\$4.9M)
- Strategic investor group (\$7.4M)
- OCS (\$2.8M)



Chief Executive Officer
Charles S. Irving, Ph.D

Therapeutic focus: Development of cell therapies for retinal and neural degenerative diseases using human embryonic stem cells

Lead product candidate: OpRegen®, proven to slow disease progression of severe dry AMD (age-related macular degeneration)

Stage: IND application approved by FDA; and received the necessary approvals for initiating Phase I/IIa clinical study of lead product candidate, OpRegen® at Hadassah Ein Kerem Medical Center in Jerusalem, Israel
Granted Key US Patent for Retinal Pigment Epithelial (RPE) Stem Cells



Competitive Advantage

The FDA-approved OpRegen® will be the first preparation of xeno-free human embryonic stem cell-derived RPE cells evaluated for transplant therapy of dry AMD

Market Opportunity:

- No FDA approved therapy for dry AMD
- There are about 1.6 million new cases of dry-AMD in the US annually , yearly economic loss in US has been estimated \$24.4B
- Estimated 973,000 AMD patients with potential to benefit from CellCure therapy , worldwide market opportunity > \$5B/yr.

Investments: \$23.9M

- HBL (\$5.1M)
- Teva Pharmaceutical (\$3.2M)
- Bio-Time (\$9.2M)
- OCS (\$6.4M)



Chief Executive Officer
Noam Shani, Ph.D

Therapeutic focus: Development of novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases based on its proprietary dual signaling protein (DSP)

Lead product candidate: KAHR-102 is a fusion protein that links portions of two immune and cancer-related membrane proteins: CTLA-4 and FasL

Stage: Advanced preclinical stages with lead product KAHR-102 for cancer indication; preparing for phase I/II trial during 2015



Competitive Advantage

Bi-functional biological drugs offering personalized medicine with superior activity and lower toxicity

Market Opportunity:

- Lymphoma and autoimmune diseases
- Comparable drugs for both cancer and autoimmune are being sold for several Billions of US \$ annually
- The market for lymphoma and autoimmune diseases is estimated to be over 30 B of US \$

Investments: \$12.6M

- HBL (\$3.9M)
- Sanofi (\$3M)
- Recipharm (\$3.7M)
- OCS (\$1.9M)



Chief Executive Officer
Alex Kozak, Ph.D

Therapeutic focus: Developing innovative targeted drug for CNS conditions

Lead product candidate : THR-18 allows SAFE thrombolysis with existing stroke medication

Stage: A THR-18 phase II/a clinical trial in acute ischemic stroke patients treated tPA (Alteplase) has been successfully completed

Market opportunity: Three patented CNS drugs in phase II clinical trials for large markets

Investments: Holdings through merger with Thrombotech, previously a subsidiary of HBL



Chief Executive Officer
Shira Yair BSc. MBA

Therapeutic focus: Development of novel therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune and inflammatory diseases

Lead product candidate: Prozumab, a promising monoclonal antibody with a unique mechanism of action currently in late-stage preclinical development for the treatment of Inflammatory Bowel Disease (IBD)

Stage: Pre-clinical proof of concept studies, rodent toxicology, CMC and pre-IND meeting with the FDA completed; additional pre-clinical proof of concept studies in orphan disease indications underway



Competitive Advantage

Prozumab is a first-in class humanized anti-HSP60 monoclonal antibody utilizing a unique mechanism of action for the treatment of autoimmune inflammatory diseases.

Market Opportunity:

- Global IBD market to reach \$9.6B in 2017

Investments: \$9.1M

- HBL (\$3.6M)
- Pontifax (\$1.65M)
- CBI (\$1.65M)
- OCS (\$2.2M)



Therapeutic focus: Development of a cluster of high value tumor biomarkers for pre-cancer alert, early detection and prediction of colorectal cancer (CRC) risk and response

Lead product candidate: Colon-MarCarePlex™, the first IVD plasma RNA test for CRC, based on a panel of biomarkers

Stage: Completed clinical trials of over 1000 human plasma samples ; patent application has been submitted ; reaching for strategic partner \ commercialization

Competitive Advantage

High sensitivity and specificity blood based technology offering potential alternative to invasive diagnostic methods

Market Opportunity:


- Colon and rectal cancer diagnostics generate ~\$3.7 billion in US revenue per year

Investments: \$3.9M

- HBL (\$1.7M)
- Micromedic (\$1M)
- OCS (\$1.2M)

Advancement

Maturity point for our current portfolio companies for strategic / financial deals



FUTURE PLAN

- Leading our current portfolio companies to commercialization by reaching inflection points
- Broaden our portfolio with new projects in fields such as *pharmaceuticals, medical devices and e-Health*
- Leverage governmental funds for early stage investments
- Establish presence in China through strategic partnership
- Expand relationships with Big Pharma companies



Hadasit
Bio-Holdings Ltd.

Thank you

